



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2010-022713-26/ Novartis Protocol ID CAMN107DDE12

*Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at least 1 year of adjuvant imatinib mesylate*

Trial CAMN107DDE12 was cancelled with no patient enrollment and as such, no results will be reported.